Eloxx Pharmaceuticals Reprices CEO Stock Options
Company Announcements

Eloxx Pharmaceuticals Reprices CEO Stock Options

Eloxx Pharmaceuticals ( (ELOX) ) just unveiled an update.

Eloxx Pharmaceuticals has approved a significant stock option repricing, reducing the exercise price of its CEO’s options to a mere $0.0001, aligning with the closing stock price on October 16, 2024. This move, part of the 2018 Equity Incentive Plan, also accelerates the exercisability of these options, providing immediate full access regardless of previous vesting conditions. This strategic adjustment highlights the company’s effort to align executive incentives with shareholder interests.

See more data about ELOX stock on TipRanks’ Stock Analysis page.

Related Articles
TheFlyEloxx Pharmaceuticals provides ELX-02, ZKN-013 program updates
TheFlyEloxx Pharmaceuticals treatment of Alport Syndrome granted FDA orphan status
Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App